Chronic Inflammatory Disease Clinical Trial
Official title:
A Double-blind, Randomized, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single- and Multiple-ascending Doses of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
A Phase 1, first in human (FIH), single-centre, double-blind, randomized, placebo-controlled, dose escalating trial to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of CBS001 in healthy subjects. The study will be conducted in 2 parts: Part A: Single ascending intravenous (IV) doses of CBS001 Part B: Multiple ascending IV doses of CBS001
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04327752 -
Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease
|
||
Recruiting |
NCT04334031 -
Deployment o the Multidisciplinary Prospective Cohort Imminent
|
N/A | |
Active, not recruiting |
NCT02332460 -
Infusion Related Reactions in Patients Receiving Infliximab
|
||
Recruiting |
NCT05613712 -
Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine
|